Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in menu_set_active_trail() (line 2405 of /mnt/stor5-wc1-dfw1/644438/www.adrenaltumors.org/web/content/includes/menu.inc).

News & Updates

Subscribe to News & Updates feed News & Updates
NCBI: db=pubmed; Term=adrenal tumor
Updated: 3 days 12 hours ago

adrenal tumor; +31 new citations

Fri, 11/08/2019 - 15:27

31 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

adrenal tumor

These pubmed results were generated on 2019/11/08

PubMed comprises more than millions of citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

A Unique Combined Ganglioneuroma Schwannoma Tumor Mimicking Adrenal Malignancy.

Fri, 11/01/2019 - 14:03
Related Articles

A Unique Combined Ganglioneuroma Schwannoma Tumor Mimicking Adrenal Malignancy.

Cureus. 2019 Aug 27;11(8):e5500

Authors: Porter KR, Shroff S, Tran TA, Neychev V

Abstract
A 28-year-old woman with a past medical history significant for cervical cancer was diagnosed with a 2.5 cm adrenal tumor but was lost to follow-up. Two years later, she presented to the emergency room with worsening right upper abdominal and flank pain. The computed tomography (CT) and magnetic resonance imaging (MRI) of the abdomen and pelvis revealed that the right adrenal mass had nearly doubled in size (4.3 cm), was heterogeneous with calcifications, central necrosis and actively uptaking the intravenous (IV) contrast with a delayed washout. The biochemical workup was negative for hyperaldosteronism, hypercortisolism, and pheochromocytoma. She reported an unintentional body weight loss of 40 pounds. Adrenocortical carcinoma or a metastatic malignancy was high on the differential diagnoses list. She underwent a successful laparoscopic adrenalectomy, and final pathology revealed a benign extra-adrenal combined ganglioneurofibroma and schwannoma. These rare benign malignancies alone or in combination may closely mimic the clinical and imaging characteristics of adrenal malignancy and pose a diagnostic and therapeutic dilemma to surgeons as well as cause a significant distress to patients and their families. Thus, it is important to thoroughly document and report these cases in order to increase awareness and improve our understanding of the biology, natural history and management of these extremely rare tumors.

PMID: 31667035 [PubMed]

Giant abdominal tumor - would you think adrenal?

Fri, 11/01/2019 - 14:03
Related Articles

Giant abdominal tumor - would you think adrenal?

Rom J Morphol Embryol. 2019;60(2):691-695

Authors: Tica I, Moroşan V, Micu LG, Niculescu C, Mehedinţi MC, Coman M, Crăiţoiu Ş, Iacov-Crăiţoiu MM, Tica VI, Niculescu Z

Abstract
Adrenal cavernomas are rare benign tumors, and those of giant dimensions are exceptional. Usually, they are symptomless or they induce symptoms and signs due to compression over nearby organs. We present the case of a 68-year-old woman, who complained of abdominal enlargement and abdominal pain in the left part of the abdomen. Imagistic investigations (native and contrast abdominal computed tomography) revealed an inhomogeneous retroperitoneal mass of 210∕182∕200 mm, containing calcifications. Laboratory findings were not relevant, just a slight and non-significant elevation of carcinoembryonic antigen and a slight elevation of C-reactive protein. Diagnosis of cancer of undetermined origin was considered, and surgery was performed. During surgery, a giant encapsulated inhomogeneous tumor of 330 mm, with cystic areas, was removed, without assessing the origin. Primary or secondary tumors (metastasis from breast, intestinal, lung, renal or skin cancer) were taken into account. Only histopathology and immunohistochemistry revealed the diagnosis of adrenal cavernoma. Until this moment, we found only one published article in the medical literature with similar dimensions of an adrenal cavernoma as in our case. Even if rare, hemangioma of the adrenal gland must be considered during the differential diagnosis of an adrenal tumor.

PMID: 31658346 [PubMed - in process]

Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer.

Fri, 11/01/2019 - 14:03
Related Articles

Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer.

J Thorac Dis. 2019 Sep;11(9):3836-3845

Authors: Takahashi Y, Adachi H, Mizukami Y, Yokouchi H, Oizumi S, Watanabe A

Abstract
Background: The efficacy of curative-intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with certain types of oligometastases, particularly brain and adrenal metastases, has previously been described. We investigated the outcomes of curative-intent pulmonary resection for NSCLC patients with synchronous isolated bone metastases, which have been less clear to date.
Methods: We retrospectively reviewed the clinical and pathological records of 41 patients with NSCLC and synchronous isolated bone metastases who underwent radical treatments (surgery and/or chemotherapy and/or radiotherapy) for both their primary tumors and bone metastases at the National Hospital Organization, Hokkaido Cancer Center, between 2008 and 2013.
Results: Nine of the 41 patients underwent pulmonary primary tumor resection; the rate of clinical N0-1 disease among these 9 patients (100%) was significantly higher than that among the 32 patients who did not undergo resection (34.4%). The five-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates of the nine patients who underwent pulmonary resection were 66.7%, 55.6%, and 44.4%, respectively. On multivariate analysis, the predictors of longer OS among all 41 patients were primary site resection [hazard ratio (HR) =4.18, 95% CI, 1.20-14.6, P=0.025] and epidermal growth factor receptor (EGFR) mutation (HR =3.30, 95% CI, 1.08-10.1, P=0.036). The former was also a predictor of longer PFS (HR =3.75, 95% CI, 1.27-11.0, P=0.016).
Conclusions: Patients with clinical N0-1 NSCLC and synchronous isolated bone metastases may achieve longer survival rates following primary lung tumor resection.

PMID: 31656656 [PubMed]

Canine adrenocorticotropic hormone-producing sinusoidal neuroendocrine tumor associated with Cushing's disease.

Fri, 11/01/2019 - 14:03
Related Articles

Canine adrenocorticotropic hormone-producing sinusoidal neuroendocrine tumor associated with Cushing's disease.

J Vet Med Sci. 2019 Oct 28;:

Authors: Baek YB, Ang MJ, Park JG, Yu DH, Park S, Lee JH, Choi J, Cho KO

Abstract
An 18-year-old male Yorkshire Terrier was admitted with a history of neurological signs including dullness and progressive tetraparesis. Physical examination revealed bilaterally symmetrical alopecia and pot-bellied abdomen. Computed tomography and necropsy examination showed a mass across the frontal sinus and cerebral frontal lobe, bilateral adrenocortical hyperplasia, and hepatomegaly. Histopathologically, the tumor lesions consisted of sheets, nests, or cords of small- to medium-sized round-to-polyhedral cells. Adrenal cortex showed bilateral diffuse cellular proliferation, and some hepatocytes showed intracytoplasmic glycogen accumulation. Immunohistochemically, the tumor cells were positive for pancytokeratin, chromogranin-A, neuron-specific enolase, S100, synaptophysin, and thyroid transcription factor-1 but negative for microtubule-associated proein-2 and neurofilament, leading to the diagnosis of neuroendocrine tumor. These tumor cells were also positive for adrenocorticotropic hormone.

PMID: 31656239 [PubMed - as supplied by publisher]

Pseudopheochromocytoma.

Fri, 11/01/2019 - 14:03
Related Articles

Pseudopheochromocytoma.

Endocrinol Metab Clin North Am. 2019 Dec;48(4):751-764

Authors: Mamilla D, Gonzales MK, Esler MD, Pacak K

Abstract
Pseudopheochromocytoma manifests as severe, symptomatic paroxysmal hypertension without significant elevation in catecholamine and metanephrine levels and lack of evidence of tumor in the adrenal gland. The clinical manifestations are similar but not identical to those in excess circulating catecholamines. The underlying symptomatic mechanism includes augmented cardiovascular responsiveness to catecholamines alongside heightened sympathetic nervous stimulation. The psychological characteristics are probably attributed to the component of repressed emotions related to a past traumatic episode or repressive coping style. Successful management can be achieved by strong collaboration between a hypertension specialist and a psychiatrist or psychologist with expertise in cognitive-behavioral panic management.

PMID: 31655774 [PubMed - in process]

Sex-differences in [68Ga]Ga-DOTANOC biodistribution.

Fri, 11/01/2019 - 14:03
Related Articles

Sex-differences in [68Ga]Ga-DOTANOC biodistribution.

Nucl Med Biol. 2019 Aug 28;76-77:15-20

Authors: Leisser A, Lukic K, Nejabat M, Wadsak W, Mitterhauser M, Mayerhöfer M, Karnaikas G, Raderer M, Hacker M, Haug AR

Abstract
INTRODUCTION: Still little is known about factors, influencing the organ uptake of somatostatin receptor (SSTR)-targeting radiopharmaceuticals. The aim of this study was to assess the influence of gender on [68Ga]Ga-DOTANOC uptake. Further on, we assessed other factors such as diabetes, proton pump inhibitors (PPIs) and oral antidiabetics (OADs).
METHODS: In 118 studies of patients with a [68Ga]Ga-DOTANOC PET/CT (m = 60, f = 58; mean age: 61 ± 15 yrs) SUVmax and SUVmean of the stomach, liver, spleen, kidneys, adrenal glands, and pancreas were assessed. Patients with history of splenectomy and significant tumor burden were excluded. Additionally, clinical information (gender, diabetes, age, pre-medications such as PPIs, OADs and somatostatin analogues (SSAs), were collected.
RESULTS: [68Ga]Ga-DOTANOC uptake proved to be significantly lower in female patients compared to males for the SUVmax of the stomach (7.1, 9.1; P = 0.04), liver (8.3, 9.4; P = 0.0007), adrenal glands (15.9, 19.9; P = 0.05) kidneys (20.3, 18.9; P = 0.05) and the SUVmean of the pancreatic tail (2.9, 3.2; P = 0.03) and the kidneys (11.8, 10.6, P = 0.004). Additionally, patients with diabetes and below the age of 50 yrs. showed significantly higher SUVmax and SUVmean values of the stomach (diabetes: 9.1, 7.8; P = 0.01 and 6.0, 5.3; P = 0.004; age: 6.3, 8.3; P = 0.01 and 4.4, 5.5; P = 0.03). In contrast, intake of PPIs only affected the SUVmean of the liver (11.0, 9.0; P = 0.005), whereas OADs caused higher SUVmax values in the stomach (10.0, 7.8; P = 0.02), spleen (42.5, 32.6; P = 0.0005) adrenal glands (25.0, 16.9; P = 0.0003) and also higher SUVmean in the spleen (26.1, 21.4; P = 0.002) and adrenal glands (14.8, 12.4; P = 0.02).
CONCLUSION: Factors such as gender, diabetes and age influence [68Ga]Ga-DOTANOC uptake, whereas ongoing medications such as PPIs and OADs exerted less influence.

PMID: 31654811 [PubMed - as supplied by publisher]

Outcome and long-term follow-up of adrenal lesions in multiple endocrine neoplasia type 1.

Fri, 11/01/2019 - 14:03
Related Articles

Outcome and long-term follow-up of adrenal lesions in multiple endocrine neoplasia type 1.

Arch Endocrinol Metab. 2019;63(5):516-523

Authors: Ventura M, Melo M, Carrilho F

Abstract
OBJECTIVE: To describe the prevalence, clinical characteristics and outcome of adrenal lesions in long-term follow-up of Multiple endocrine neoplasia type 1 (MEN1) patients.
SUBJECTS AND METHODS: We retrospectively studied sixteen patients from six families of individuals with MEN1. Adrenal involvement was evaluated using clinical, biochemical and imaging data.
RESULTS: Adrenal lesions were identified in nine of sixteen (56.3%) patients: seven women and two men (mean age: 52.2 years). Adrenal involvement was detected at MEN1 diagnosis in more than half of the patients. Eighteen adrenal nodules were founded (median of two nodules per patient) with mean adrenal lesion diameter of 17.4 mm. Three patients had unilateral adrenal involvement. Hormonal hypersecretion (autonomous cortisol secretion) was found in two patients. None of the patients was submitted to adrenalectomy, presented an aldosterone-secreting lesion, a pheochromocytoma, an adrenal carcinoma or metastatic disease during the follow-up. A predominance of stable adrenal disease, in terms of size and hormonal secretion, was observed. Adrenal lesions were evenly distributed between the germline mutations.
CONCLUSION: Adrenal tumours are a common feature of MEN1 that can affect more than half of the patients. Most of the tumours are bilateral non-functional lesions, but hormonal secretion may occur and should be promptly identified to reduce the morbidity/mortality of the syndrome. Periodic surveillance of these patients should be performed.

PMID: 31482957 [PubMed - indexed for MEDLINE]

18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.

Fri, 11/01/2019 - 14:03
Related Articles

18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.

Clin Nucl Med. 2019 Sep;44(9):738-740

Authors: Lugat A, Drui D, Mirallié E, Kraeber-Bodéré F, Ansquer C

Abstract
We report the case of a 23-year-old man presenting a right hypersecreting pheochromocytoma, falsely negative on F-FDG PET/CT and on I-metaiodobenzylguanidine (I-MIBG) scintigraphy but strongly positive on F-FDOPA PET/CT. Functional imaging has a key role in diagnosis and prognosis of pheochromocytomas, but choosing the most relevant modality remains difficult. Despite its high specificity, I-MIBG has a limited sensitivity. F-FDG can be used, but it is an unspecific tracer, and F-FDG uptake in brown adipose tissue can hinder the analysis. However, F-FDOPA shows very high sensitivity and specificity in pheochromocytomas with fewer drug interferences than I-MIBG.

PMID: 31306205 [PubMed - indexed for MEDLINE]

Bilateral Adrenal Extremely Intense Metabolic Activity on 18F-FDG PET/CT in a Patient With Pheochromocytomas.

Fri, 11/01/2019 - 14:03
Related Articles

Bilateral Adrenal Extremely Intense Metabolic Activity on 18F-FDG PET/CT in a Patient With Pheochromocytomas.

Clin Nucl Med. 2019 Sep;44(9):748-749

Authors: Chen X, Chen G, Fu Z, Li Q

Abstract
Bilateral adrenal masses were found by ultrasound on a 55-year-old man with sudden onset of chest distress and palpitation after drinking alcohol. After the negative laboratory tests of plasma catecholamine and urinary vanillylmandelic acid, the F-FDG PET/CT revealed extremely intense metabolic activity in the bilateral adrenal lesions, and the subsequent I-meta-iodobenzylguanidine scintigraphy also showed increased radioactivity in the lesions. The pathology of surgery confirmed the diagnosis of bilateral pheochromocytomas.

PMID: 31107752 [PubMed - indexed for MEDLINE]

Concurrent Metastatic Pheochromocytomas and Lung Adenocarcinoma on 18F-FDG and 68Ga-DOTATATE PET/CT Images.

Fri, 11/01/2019 - 14:03
Related Articles

Concurrent Metastatic Pheochromocytomas and Lung Adenocarcinoma on 18F-FDG and 68Ga-DOTATATE PET/CT Images.

Clin Nucl Med. 2019 Sep;44(9):754-756

Authors: Cheng Z, Zou S, Song S, Zhu X

Abstract
Both F-FDG and Ga-DOTATATE PET/CT are used in the evaluation of pheochromocytomas. We reported F-FDG and Ga-DOTATATE PET/CT findings in a 60-year-old man who had recurrent metastatic pheochromocytoma coexisting with lung adenocarcinoma. The metastatic pheochromocytoma showed increased activity on both F-FDG and Ga-DOTATATE PET/CT, whereas the lung adenocarcinoma lesion showed no obvious DOTATATE activity.

PMID: 31021913 [PubMed - indexed for MEDLINE]

Outcomes Following Proton Therapy for Pediatric Low-Grade Glioma.

Fri, 11/01/2019 - 14:03
Related Articles

Outcomes Following Proton Therapy for Pediatric Low-Grade Glioma.

Int J Radiat Oncol Biol Phys. 2019 05 01;104(1):149-156

Authors: Indelicato DJ, Rotondo RL, Uezono H, Sandler ES, Aldana PR, Ranalli NJ, Beier AD, Morris CG, Bradley JA

Abstract
PURPOSE: Dosimetric studies show that proton therapy can reduce the low/intermediate radiation dose to uninvolved tissue in children with low-grade glioma (LGG). For this reason, LGG is the fourth most common pediatric tumor treated with proton therapy, yet clinical outcome data on efficacy and toxicity are limited.
METHODS AND MATERIALS: We reviewed the medical records of 174 children (≤21 years old) with nonmetastatic LGG enrolled on a prospective protocol and treated with proton therapy between 2007 and 2017. We assessed clinical outcomes and toxicity and analyzed patient, tumor, and treatment-related variables.
RESULTS: The median age was 10.2 years (range, 2-21). Fifty-eight percent of tumors were World Health Organization grade 1 and 30% were grade 2; 12% were diagnosed on imaging characteristics alone. The most common histology was pilocytic astrocytoma (47%). The most common tumor subsites were diencephalon/optic pathway (52%), caudal brainstem (16%), and cerebellum (13%). Forty-two percent received chemotherapy before radiation therapy. The median follow-up was 4.4 years. The 5-year actuarial rates of local control, progression-free survival, and overall survival were 85% (95% confidence interval [CI], 78%-90%), 84% (95% CI, 77%-89%), and 92% (95% CI, 85%-95%), respectively. On univariate analysis, brainstem/spinal cord tumor location (62% vs 90% elsewhere) and dose <54 GyRBE (67% vs 91% for 54 GyRBE) were associated with inferior local control (P < .01 for both). Twenty-two patients (12.6%) experienced acute nausea or vomiting requiring ondansetron; 2 patients (1.1%) required corticosteroids. Serious toxicities (4% of patients) included brainstem necrosis requiring corticosteroids (n = 2), symptomatic vasculopathy (n = 2), radiation retinopathy (n = 1), epilepsy (n = 1), and death from radiation-induced high-grade glioma (n = 1). Thirty-nine patients (22%) developed new-onset central hormone deficiency. Pseudoprogression was observed in 32.1%.
CONCLUSIONS: Compared with modern photon series, proton therapy reduces the radiation dose to developing brain tissue, diminishing acute toxicities without compromising disease control.

PMID: 30684665 [PubMed - indexed for MEDLINE]

Androgens in women: Androgen-mediated skin disease and patient evaluation.

Fri, 11/01/2019 - 14:03
Related Articles

Androgens in women: Androgen-mediated skin disease and patient evaluation.

J Am Acad Dermatol. 2019 Jun;80(6):1497-1506

Authors: Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR

Abstract
Androgens are produced throughout the body in steroid-producing organs, such as the adrenal glands and ovaries, and in other tissues, like the skin. Several androgens are found normally in women, including dehydroepiandrosterone, dehydroepiandrosterone-sulfate, testosterone, dihydrotestosterone, and androstenedione. These androgens are essential in the development of several common cutaneous conditions in women, including acne, hirsutism, and female pattern hair loss (FPHL)-androgen-mediated cutaneous disorders (AMCDs). However, the role of androgens in the pathophysiology of these diseases is complicated and incompletely understood. In the first article in this Continuing Medical Education series, we discuss the role of the skin in androgen production and the impact of androgens on the skin in women. Specifically, we review the necessary but insufficient role that androgens play in the development of acne, hirsutism, and FPHL in women. Dermatologists face the challenge of differentiating physiologic from pathologic presentations of AMCDs in women. There are currently no dermatology guidelines outlining the indications for endocrinologic evaluation in women presenting with acne, hirsutism, or FPHL. We review the available evidence regarding when to consider an endocrinologic workup in women presenting with AMCDs, including the appropriate type and timing of testing.

PMID: 30312644 [PubMed - indexed for MEDLINE]

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

Fri, 11/01/2019 - 14:03
Related Articles

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

J Immunother Cancer. 2018 10 11;6(1):103

Authors: Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A

Abstract
BACKGROUND: Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α inhibitors such as infliximab (IFX) may expedite symptom resolution and shorten CS duration. Thus, we conducted the first retrospective study, to our knowledge, evaluating symptom resolution in patients with irEC treated with and without IFX.
METHODS: Data were collected from the medical records of patients diagnosed with irEC. The primary endpoint was time to symptom resolution for irEC for cases managed with IFX plus CS (IFX group) versus CS alone (CS group). Duration of CS, overall survival (OS), and time to treatment failure (TTF) were secondary endpoints.
RESULTS: Among 75 patients with irEC, 52% received CS alone, and 48% received IFX. Despite higher grade colitis in the IFX group (grade 3/4: 86% vs. 34%; p < 0.001), median times to diarrhea resolution (3 vs. 9 days; p < 0.001) and to steroid titration (4 vs. 13 days; p < 0.001) were shorter in the IFX group than in the CS group without a negative impact on TTF or OS. Total steroid duration (median 35 vs. 51 days; p = 0.150) was numerically lower in the IFX group.
CONCLUSIONS: Despite higher incidence of grade 3/4 colitis, IFX added to CS for the treatment of patients with irEC was associated with a significantly shorter time to symptom resolution. The data suggest that early introduction of IFX should be considered for patients with irEC until definitive prospective clinical trials are conducted.

PMID: 30305177 [PubMed - indexed for MEDLINE]

Phenoxybenzamine Is Unlikely to Be the Intraoperative Antihypertensive of Choice in Pheochromocytoma.

Fri, 11/01/2019 - 14:03
Related Articles

Phenoxybenzamine Is Unlikely to Be the Intraoperative Antihypertensive of Choice in Pheochromocytoma.

Ann Thorac Surg. 2019 02;107(2):688-689

Authors: Grocott HP

PMID: 30248322 [PubMed - indexed for MEDLINE]

[Sinus tachycardia in pregnancy].

Fri, 11/01/2019 - 14:03
Related Articles

[Sinus tachycardia in pregnancy].

Ugeskr Laeger. 2018 Aug 20;180(34):

Authors: Kofod LM, Lauszus F

Abstract
Sinus tachycardia may have a definite aetiology, but in the remaining cases inappropriate sinus tachycardia (IST) may be considered. IST is primarily treated in order to improve symptoms. During pregnancy, tachycardia-induced cardiomyopathy is rare; however, it needs urgent attention and treatment due to the risk of fast progression. In Denmark, performing an electrocardiogram is recommended in any pregnant woman, who has palpitations or a persisting heart rate > 100 beats per minute.

PMID: 30152314 [PubMed - indexed for MEDLINE]

Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis.

Fri, 11/01/2019 - 14:03
Related Articles

Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis.

J Nucl Med. 2019 03;60(3):369-376

Authors: Han S, Suh CH, Woo S, Kim YJ, Lee JJ

Abstract
We performed a systematic review and metaanalysis of the performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide (68Ga-DOTA-SST) PET in the detection of pheochromocytomas and paragangliomas (PPGLs). Methods: PubMed and Embase were searched until May 8, 2018. We included studies that reported the detection rate of 68Ga-DOTA-SST PET in patients with PPGLs. Detection rates were pooled using a random-effects model. Subgroup analyses and metaregression were performed to explore the cause of heterogeneity. Results: Thirteen studies were included for qualitative synthesis. Per-lesion detection rates of 68Ga-DOTA-SST PET were consistently higher (ranging from 92% to 100%) than other imaging modalities, including 18F-fluorohydroxyphenylalanine (18F-FDOPA) PET, 18F-FDG PET, and 123/131I-metaiodobenzylguanidine (123/131I-MIBG) scintigraphy. However, in patients with polycythemia/paraganglioma syndrome, the detection rate of 68Ga-DOTA-DOTATATE PET was 35%. Nine studies (215 patients) with no specific inclusion criteria for subtype were quantitatively synthesized. The pooled detection rate was 93% (95% confidence interval [CI], 91%-95%), which was significantly higher than that of 18F-FDOPA PET (80% [95% CI, 69%-88%]), 18F-FDG PET (74% [95% CI, 46%-91%]), and 123/131I-MIBG scan (38% [95% CI, 20%-59%], P < 0.001 for all). A greater prevalence of head and neck paragangliomas was associated with higher detection rates of 68Ga-DOTA-SST PET (P = 0.0002). Conclusion: 68Ga-DOTA-SST PET exhibited superior performance for lesion detection, over other functional imaging modalities, in patients with PPGLs, with the exception of polycythemia/paraganglioma syndrome. This might suggest 68Ga-DOTA-SST PET as a first-line imaging modality for the primary staging of PPGL or the restaging of PPGL with unknown genetic status.

PMID: 30030341 [PubMed - indexed for MEDLINE]

Catecholamine crisis during induction of general anesthesia : A case report.

Fri, 11/01/2019 - 14:03
Related Articles

Catecholamine crisis during induction of general anesthesia : A case report.

Anaesthesist. 2018 03;67(3):209-215

Authors: Sonntagbauer M, Koch A, Strouhal U, Zacharowski K, Weber CF

Abstract
Catecholamine crises associated with pheochromocytoma may cause life-threatening cardiovascular conditions. We report the case of a 75-year-old male who developed a hypertensive crisis during induction of general anesthesia for elective resection of a cervical neuroma due to an undiagnosed pheochromocytoma. Hemodynamic instability occurred immediately after the injection of fentanyl, propofol and rocuronium, prior to laryngoscopy and in the absence of any manipulation of the abdomen. In this case report, we present the management of this incident and discuss the underlying pathophysiology triggering a catecholamine crisis.

PMID: 29404657 [PubMed - indexed for MEDLINE]

Splenic oligometastasis: Report of a patient successfully treated with stereotactic body radiation therapy.

Fri, 10/25/2019 - 11:08
Related Articles

Splenic oligometastasis: Report of a patient successfully treated with stereotactic body radiation therapy.

J Radiosurg SBRT. 2019;6(2):157-159

Authors: Juloori A, Parsai S, Stephans K

Abstract
The use of SRS/SBRT has been extensively reported on for tumors of the lung, liver, pancreas, adrenal gland, brain, and spine. Tumor control and associated toxicities of treatment are well understood and the use of SBRT in these sites is well-accepted. Here we uniquely report a detailed case of SBRT to the spleen and demonstrate pre- and post-treatment imaging along with treatment planning implications. We demonstrate excellent local control at 4 year follow-up with no development of late toxicity.

PMID: 31641552 [PubMed]

Cohort profile: the Biology, Affect, Stress, Imaging and Cognition (BASIC) study on perinatal depression in a population-based Swedish cohort.

Fri, 10/25/2019 - 11:08
Related Articles

Cohort profile: the Biology, Affect, Stress, Imaging and Cognition (BASIC) study on perinatal depression in a population-based Swedish cohort.

BMJ Open. 2019 Oct 22;9(10):e031514

Authors: Axfors C, Bränn E, Henriksson HE, Hellgren C, Kunovac Kallak T, Fransson E, Lager S, Iliadis SI, Sylvén S, Papadopoulos FC, Ekselius L, Sundström-Poromaa I, Skalkidou A

Abstract
PURPOSE: With the population-based, prospective Biology, Affect, Stress, Imaging and Cognition (BASIC) cohort, we aim to investigate the biopsychosocial aetiological processes involved in perinatal depression (PND) and to pinpoint its predictors in order to improve early detection.
PARTICIPANTS: From September 2009 to November 2018, the BASIC study at Uppsala University Hospital, Sweden, has enrolled 5492 women, in 6478 pregnancies, of which 46.3% first-time pregnancies and with an average age of 31.5 years. After inclusion around gestational week 16-18, participants are followed-up with data collection points around gestational week 32, at childbirth, as well as three times postpartum: after 6 weeks, 6 months and 1 year. At the last follow-up, 70.8% still remain in the cohort.
FINDINGS TO DATE: In addition to internet-based surveys with self-report instruments, participants contribute with biological samples, for example, blood samples (maternal and from umbilical cord), biopsies (umbilical cord and placenta) and microbiota samples. A nested case-control subsample also takes part in cognitive and emotional tests, heart rate variability tests and bioimpedance tests. Subprojects have identified various correlates of PND of psychological and obstetric origin in addition to factors of the hypothalamic-pituitary-adrenal axis and immune system.
FUTURE PLANS: In parallel with the completion of data collection (final follow-up November 2019), BASIC study data are currently analysed in multiple subprojects. Since 2012, we are conducting an ongoing follow-up study on the participants and their children up to 6 years of age (U-BIRTH). Researchers interested in collaboration may contact Professor Alkistis Skalkidou (corresponding author) with their request to be considered by the BASIC study steering committee.

PMID: 31641004 [PubMed - in process]

Pages